Added 7 days ago Drug news

FDA approves Cobas vivoDx MRSA diagnostic test for detection of bacterial infection.- Roche

The FDA has authorized marketing of the Cobas vivoDx MRSA diagnostic test, from Roche, based on bacterial viability and novel...

Added 1 month ago Drug news

FDA approves Talicia for Helicobacter pylori (H. pylori) infection.- RedHill Biopharma

RedHill Biopharma announced that the FDA has approved Talicia (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg1/250 mg/12.5 mg...

Added 1 month ago Drug news

FDA approves Baxdela for the treatment of community-acquired bacterial pneumonia (CABP). -Melinta Therapeutics

Melinta Therapeutics, Inc. announced the FDA has approved Baxdela (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia...

Fever in under 5s: assessment and initial management

This guideline covers the assessment and early management of fever with no obvious cause in children aged under 5. It aims to improve clinical assessment and help healthcare professionals diagnose serious illness among young children...

Added 6 years ago

Surgical site infections: prevention and treatment

This guideline covers preventing and treating surgical site infections in adults, young people and children who are having a surgical procedure involving a cut through the skin.

Added 11 years ago

Guidelines on Urological Infections

The European Association of Urology (EAU) Urological Infections Guidelines Panel has compiled these clinical guidelines to provide medical professionals with evidence-based information and recommendations for...

Added 3 years ago

AR-13 reduces antibiotic-resistant bacterial burden in cystic fibrosis phagocytes and improves cystic fibrosis transmembrane conductance regulator function.

Background: There are no effective treatments for Burkholderia cenocepacia in patients with cystic fibrosis (CF) due to bacterial multi-drug resistance and defective host killing. We demonstrated that decreased bacterial...

Added 1 month ago

Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.

The CFTR potentiator, ivacaftor (IVA), has been widely used in the treatment of cystic fibrosis (CF) patients with the G551D mutation. To date, there has been limited information on the microbiological status...

Added 1 year ago

Early goal-directed therapy in the treatment of severe sepsis and septic shock.

Goal-directed therapy has been used for severe sepsis and septic shock in the intensive care unit.

Added 2 years ago